-
Meet OpenTSLM: A Family of Time-Series Language Models (TSLMs) Revolutionizing Medical Time-Series Analysis
«`html Meet OpenTSLM: A Family of Time-Series Language Models (TSLMs) Revolutionizing Medical Time-Series Analysis A significant development is set to transform AI in healthcare. Researchers at Stanford University, in collaboration with ETH Zurich and tech leaders including Google Research and Amazon, have introduced OpenTSLM, a novel family of Time-Series Language Models (TSLMs). The Critical Blind… →
-
Effect of artificial intelligence-assisted personalized feedback on radiographic diagnostic performance of dental students: a controlled study
CONCLUSIONS: ChatGPT-4o based personalized feedback proved to be an effective tool for enhancing diagnostic performance and supporting learning in dental education. The findings suggest that AI-driven individualized educational strategies hold significant potential in the future of dental training. →
-
Comparative efficacy of 200 mg versus 1200 mg of simethicone with 3 L polyethylene glycol electrolyte solution for afternoon colonoscopy: a randomized controlled trial
CONCLUSION: 200 mg versus 1200 mg of SIM in 3 L PEG-ELS for afternoon colonoscopy demonstrated no statistically significant difference in bowel cleansing quality, ADR and bowel preparation-related adverse events. This evidence supports the clinical feasibility of 200 mg simethicone as an effective alternative for optimizing colonic preparation while maintaining procedural standards. →
-
Sputum colour charts to guide antibiotic self-treatment of acute exacerbation of chronic obstructive pulmonary disease: the Colour-COPD RCT
CONCLUSION: Under-recruitment precluded definitive conclusions. However, sputum colour is unlikely to be a useful addition to COPD SM in primary care. →
-
Liquid AI Releases LFM2-8B-A1B: An On-Device Mixture-of-Experts with 8.3B Params and a 1.5B Active Params per Token
Liquid AI Releases LFM2-8B-A1B: An On-Device Mixture-of-Experts with 8.3B Params and a 1.5B Active Params per Token Understanding the Target Audience The primary audience for the LFM2-8B-A1B release includes: Business Decision Makers: They seek to integrate advanced AI capabilities into products while managing costs, performance, and system requirements. Data Scientists and AI Engineers: They are… →
-
Smart Continence Care for People With Profound Intellectual and Multiple Disabilities Within Dutch Residential Care Facilities: Economic Evaluation Alongside a Cluster Randomized Trial
CONCLUSIONS: The results of this economic evaluation are not conclusive because of the mixed outcomes and a limited timeframe. SCC is ineffective in reducing the number of weekly leakages, but it does reduce the number of weekly IMCs. However, SCC was not effective in reducing time spent on continence care. Findings suggest that SCC is… →
-
Influence of Cannabidiol Use on Visual Function and Optical Quality: A Randomized Controlled Trial
CONCLUSIONS: This non-psychotropic CBD did not appear to adversely affect vision and seems to be a safe substance in the short term at the concentrations assessed. →
-
Meta Superintelligence Labs’ MetaEmbed Rethinks Multimodal Embeddings and Enables Test-Time Scaling with Flexible Late Interaction
«`html Understanding the Target Audience for MetaEmbed The target audience for Meta Superintelligence Labs’ MetaEmbed solution primarily consists of AI and business professionals who are focused on enhancing multimodal retrieval systems. This audience typically includes data scientists, machine learning engineers, product managers, and decision-makers in organizations that rely on efficient data retrieval and processing. Audience… →
-
Comparison of the efficacy of connective tissue massage and manual lymphatic drainage in patients with migraine: a randomized controlled trial
CONCLUSIONS: These findings suggest that CTM and MLD can help migraine patients, with MLD showing a stronger effect on pain relief and well-being, whereas CTM being more effective in reducing neck pain and disability. →
-
A randomized, double blind, placebo-controlled pilot study to assess the efficacy of erenumab in individuals with temporomandibular disorder
CONCLUSIONS: Erenumab was not efficacious in reducing TMD myalgic pain in this phase II trial of 30 subjects with relatively mild pain. →
